The characterization, current medications, and promising therapeutics targets for premature ejaculation

Gur S., Sikka S. C.

ANDROLOGY, vol.3, no.3, pp.424-442, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 3 Issue: 3
  • Publication Date: 2015
  • Doi Number: 10.1111/andr.12032
  • Journal Name: ANDROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.424-442
  • Keywords: dapoxetine, intravaginal ejaculation latency time, pathophysiology, premature ejaculation, selective serotonin reuptake inhibitors, serotonin, EVIDENCE-BASED DEFINITION, URINARY-TRACT SYMPTOMS, AD-HOC COMMITTEE, BENIGN PROSTATIC HYPERPLASIA, SPINAL PATTERN GENERATOR, SEMINAL-VESICLE TISSUE, HYALURONIC-ACID GEL, DOUBLE-BLIND, MALE-RAT, INTERNATIONAL-SOCIETY
  • Ankara University Affiliated: Yes

Abstract

Premature ejaculation (PE) is the most prevalent male sexual dysfunction. This is associated with negative personal and interpersonal psychological outcomes. The pharmacologic treatment of PE includes the use of antidepressants, local anesthetic agents, and phosphodiesterase type 5 inhibitors. While numerous treatments can control PE, only antidepressants and topical anesthetic creams and sprays have recently been shown to be more effective. This review focuses on the physiology and pharmacology of ejaculation, the pathophysiology of PE and the most effective pharmacological treatment of PE. Pharmacotherapy of PE with off-label short-acting selective serotonin reuptake inhibitors (SSRIs) is common, effective, and safe. Dapoxetine, a SSRI with a short half-life, has been recently evaluated for the treatment of PE by several countries and results are promising. In clinical practice, follow-up side effects are an important part of the management strategy for PE. The understanding of etiology, pathophysiology, and treatment modalities of PE would be beneficial to clinician in helping patients with this disappointing sexual problem.